Abstract Number: 1014 • 2019 ACR/ARP Annual Meeting
Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients
Background/Purpose: Here we hypothesized that (i) IL-23/IL-23R system more specifically the specific IL-23p19 subunit mediated signaling system regulates expansion/maintenance and functional maturation in respect to…Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…Abstract Number: 62 • 2018 ACR/ARHP Annual Meeting
CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis
Background/Purpose: The IL-23/IL-17A immune pathway is important for the progression of T cell-mediated arthritis. However, it is not known where IL-23R+ T cells locate during…Abstract Number: 143 • 2018 ACR/ARHP Annual Meeting
Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
Background/Purpose: Th17, a subset of CD4+ helper T cells, provides protection against pathogens and malignancies, but also promotes immune-mediated-inflammation in a range of disorders including…Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…Abstract Number: 1028 • 2018 ACR/ARHP Annual Meeting
An Entheseal Innate Immune Cell Biological Basis for Differential Efficacy of PDE4 and IL-23 Pathway Blockade between Psoriatic Disease and Rheumatoid Arthritis
Background/Purpose: Both IL-23 and phosphodiesterase (PDE) 4 inhibition are ineffective in RA but show efficacy in PsA-related synovitis despite similar cytokine and molecular profiles between…Abstract Number: 2021 • 2018 ACR/ARHP Annual Meeting
Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis
Background/Purpose: IL-17 and IL-22 are important cytokines in pathogenesis of spondyloarthropathy. In an IL-23 or IL-22 over-expressing mouse model it was shown that enthesitis is…Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…Abstract Number: 2L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…Abstract Number: 1582 • 2017 ACR/ARHP Annual Meeting
RORγt Inhibition Selectively Targets Pathogenic Subsets of Human iNKT and γδ-T Cells Enriched in Spondyloarthritis While Preserving Tissue Protective IL-22 Responses
Background/Purpose: Dysregulated IL-23/IL-17 responses have been linked to a myriad of inflammatory diseases including psoriasis, psoriatic arthritis and other forms of spondyloarthritides (SpA). IL-23/IL-17 inflammation…Abstract Number: 1944 • 2017 ACR/ARHP Annual Meeting
A Dual Role for IL-23 Receptor Signaling in Normal Bone Remodeling Versus Inflammation-Mediated Bone Damage during Arthritis
Background/Purpose: The interleukin (IL)-23/IL-17A immune pathway is critical for the development of autoimmune arthritis. Systemic exposure of IL-23 induced chronic arthritis, increased osteoclast differentiation and…Abstract Number: 645 • 2017 ACR/ARHP Annual Meeting
An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis
Background/Purpose: Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling…Abstract Number: 659 • 2017 ACR/ARHP Annual Meeting
IL-17 Producing T Cells and Its Dichotomy: A Mixed Response of the Innate and Acquired Immune System in Psoriatic Arthritis
Background/Purpose: Source of IL-17 in human has been mainly attributed to ab T cells, more specifically to the Th17 cells. However, some reports suggest…Abstract Number: 660 • 2017 ACR/ARHP Annual Meeting
Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis
Background/Purpose: Hydrodynamic injection of IL-23 minicircles into adult B10.RIII mice induces an inflammatory disease with phenotypic features of human spondyloarthritis. Tissue-resident CD4-CD8- double negative (DN)…
ACR Meeting Abstracts